Table 1.
Patient characteristics at diagnosis
| Variable | TOTAL (n = 3055) | ER < 1% (n = 932) | 1% ≤ ER < 10% (n = 171) | ER ≥ 10% (n = 1952) | P value |
|---|---|---|---|---|---|
| Age, median (range), years | 49 (19–83) | 49 (22–83) | 49 (19–77) | 49 (22–83) | 0.49 |
| BMI, median (range), kg/m2 | 27.7 (14.5–65.9) | 27.8 (14.5–56.4) | 29 (17.7–31.3) | 27.5 (15.5–66) | 0.03 |
| Race/ethnicity | |||||
| White | 1915 (62.7) | 565 (60.6) | 97 (56.7) | 1253 (64.2) | <0.001 |
| Black | 463 (15.2) | 197 (21.1) | 35 (20.5) | 231 (11.8) | |
| Hispanic | 483 (15.8) | 128 (13.7) | 25 (14.6) | 330 (16.9) | |
| Asian/others | 194 (6.4) | 42 (4.5) | 14 (8.2) | 138 (7.1) | |
| Menopausal status | |||||
| Premenopausal | 1461 (47.8) | 438 (47.2) | 84 (49.1) | 939 (48.4) | 0.82 |
| Postmenopausal | 1579 (51.7) | 489 (52.8) | 87 (50.9) | 1003 (51.6) | |
| Unknown | 15 (0.5) | 0 (0) | 0 (0) | 0 (0) | |
| Histology | |||||
| Ductal | 2577 (84.4) | 851 (91.3) | 156 (91.2) | 1570 (80.4) | <0.001 |
| Lobular | 231 (7.6) | 15 (1.6) | 2 (1.2) | 214 (11) | |
| Others | 215 (7.0) | 40 (4.3) | 7 (4.1) | 168 (8.6) | |
| Unknown | 32 (1.0) | 26 (2.8) | 6 (3.5) | 0 (0) | |
| Nuclear grade | |||||
| I/II | 1163 (38.1) | 91 (9.8) | 19 (11.1) | 1053 (53.9) | <0.001 |
| III | 1803 (59.0) | 813 (87.2) | 148 (86.5) | 842 (43.1) | |
| Unknown | 89 (2.9) | 28 (3) | 4 (2.3) | 57 (2.9) | |
| Clinical stage | |||||
| Stage II | 1726 (56.5) | 511 (54.8) | 99 (57.9) | 1116 (57.2) | 0.46 |
| Stage III | 1329 (43.5) | 421 (45.2) | 72 (42.1) | 836 (42.8) | |
| Neoadjuvant regimen | |||||
| A | 292 (95.6) | 70 (7.5) | 9 (5.3) | 213 (10.9) | <0.001 |
| T | 112 (36.7) | 36 (3.9) | 3 (1.8) | 73 (3.7) | |
| A+T | 2651 (86.8) | 826 (88.6) | 159 (93) | 1666 (85.3) | |
| ER, continuous, mean ± SD | 51.88 ± 43.17 | – | – | – | |
| PR, categorical | |||||
| PR < 1% | 1245 (40.8) | 818 (87.8) | 110 (64.3) | 317 (16.2) | <0.001 |
| 1% ≤ PR < 10% | 326 (10.7) | 61 (6.5) | 41 (24) | 224 (11.5) | |
| PR ≥ 10% | 1484 (48.6) | 53 (5.7) | 20 (11.7) | 1411 (72.3) | |
| PR, continuous, mean ± SD | 31.6 ± 38.24 | 2.4 ± 11.3 | 4.6 ± 12.5 | 47.9 ± 38.5 | <0.001 |
| LVI | |||||
| Negative | 2030 (66.4) | 631 (67.7) | 124 (72.5) | 1275 (65.3) | 0.005 |
| Positive | 915 (30) | 254 (27.3) | 36 (21.1) | 625 (32) | |
| Unknown | 110 (3.6) | 47 (5) | 11 (6.4) | 52 (2.7) | |
| Adjuvant chemotherapy | |||||
| No | 2594 (84.9) | 770 (82.6) | 155 (90.6) | 1669 (85.5) | 0.013 |
| Yes | 461 (15.1) | 162 (17.4) | 16 (9.4) | 283 (14.5) | |
| Adjuvant hormonal therapy | |||||
| No | 1020 (33.4) | 846 (90.8) | 128 (74.9) | 46 (2.4) | <0.001 |
| Yes | 2035 (66.6) | 86 (9.2) | 43 (25.1) | 1906 (97.6) | |
| Adjuvant radiation | |||||
| No | 636 (20.8) | 237 (25.4) | 50 (29.2) | 349 (17.9) | <0.001 |
| Yes | 2419 (79.2) | 659 (74.6) | 121 (70.8) | 1603 (82.1) | |
| pCR | |||||
| No | 2626 (86) | 687 (73.7) | 123 (71.9) | 1816 (93) | <0.001 |
| Yes | 429 (14) | 245 (26.3) | 48 (28.1) | 136 (7) |
All data are no. of patients (%) unless noted otherwise.
ER, estrogen receptor; BMI, body mass index; A, anthracycline; T, taxane; SD, standard deviation; PR, progesterone receptor; LVI, lymphovascular invasion; pCR, pathological complete response.